ANDA 206233, held by Prinston. Candesartan Cilexetil.
As of Nov 15, 2026, ANDA 206233 (Candesartan Cilexetil), held by Prinston, was first approved by FDA on Aug 21, 2023, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 21, 2023 | Original application | Approved | None posted |
| Candesartan Cilexetil8MG · tablet;oral | Candesartan Cilexetil | Rx |
| Candesartan Cilexetil16MG · tablet;oral | Candesartan Cilexetil | Rx |
| Candesartan Cilexetil32MG · tablet;oral | Candesartan Cilexetil | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
